Medicamen Organics Limited

NSEI:MEDIORG Stock Report

Market Cap: ₹713.7m

Medicamen Organics Past Earnings Performance

Past criteria checks 4/6

Medicamen Organics has been growing earnings at an average annual rate of 69.8%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 0.8% per year. Medicamen Organics's return on equity is 15.8%, and it has net margins of 9.5%.

Key information

69.8%

Earnings growth rate

65.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate0.8%
Return on equity15.8%
Net Margin9.5%
Last Earnings Update31 Mar 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Medicamen Organics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:MEDIORG Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2425324340
31 Mar 2322110330
31 Mar 222101290
31 Mar 212502280
31 Mar 203151300

Quality Earnings: MEDIORG has a high level of non-cash earnings.

Growing Profit Margin: MEDIORG's current net profit margins (9.5%) are higher than last year (4.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MEDIORG's earnings have grown significantly by 69.8% per year over the past 5 years.

Accelerating Growth: MEDIORG's earnings growth over the past year (148%) exceeds its 5-year average (69.8% per year).

Earnings vs Industry: MEDIORG earnings growth over the past year (148%) exceeded the Pharmaceuticals industry 19.2%.


Return on Equity

High ROE: MEDIORG's Return on Equity (15.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies